{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T19:10:36Z","timestamp":1789413036204,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH\/NIDCR","award":["R01DE019465"],"award-info":[{"award-number":["R01DE019465"]}]},{"name":"NIH\/NIDCR","award":["R56DE033281"],"award-info":[{"award-number":["R56DE033281"]}]},{"name":"Faculty Research Grant Award","award":["RHK"],"award-info":[{"award-number":["RHK"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Medication-related osteonecrosis of the jaw (MRONJ) is a detrimental side effect in patients undergoing treatment with antiresorptive agents. The anti-angiogenic agent, bevacizumab (anti-VEGF antibody (Ab)), has also been reported to be associated with MRONJ. However, the role of anti-VEGF Ab in MRONJ development, especially under conditions of pre-existing inflammation, remains elusive. This study examined anti-VEGF Ab effects on bone necrosis and osteomucosal healing, with or without pre-inflammation. Forty mice received biweekly i.p. injections of anti-VEGF Ab (10\u00a0mg\/kg) or saline (Veh). For the tooth extraction (TE) model (\n                    <jats:italic>n<\/jats:italic>\n                    = 10), maxillary first molars were extracted. For the ligature-induced periodontitis and tooth extraction (LIP-TE) model (\n                    <jats:italic>n<\/jats:italic>\n                    = 10), maxillary second molars were ligated with 5\u22120\u00a0silk for 8 weeks before extraction. Mice were euthanized after 3 weeks of post-extraction healing. In both TE and LIP-TE models, anti-VEGF Ab-treated mice showed delayed osteomucosal healing with diminished bone formation, lower CD31 and collagen III expression, and increased osteoclast numbers than Veh-treated mice. There was no significant difference in necrotic bone areas. IL-23- or IL-17-producing cell numbers remained unchanged in both Veh- and anti-VEGF Ab-treated mice. Anti-VEGF Ab delayed osteomucosal healing by reducing collagen production in the presence or absence of pre-inflammatory conditions, without causing bone necrosis. Our data suggest anti-VEGF Ab delays osteomucosal wound healing but does not cause bone necrosis alone.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-20840-x","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T09:55:15Z","timestamp":1761126915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Anti-VEGF neutralizing antibody delays osteomucosal healing by reducing collagen formation in mice"],"prefix":"10.1038","volume":"15","author":[{"given":"Eun-Bin","family":"Bae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suk","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Woo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Esmaeili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry S.","family":"Baik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sol","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tetradis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No-Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousang","family":"Gwack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuben H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"20840_CR1","doi-asserted-by":"publisher","unstructured":"Miyoshi, T. et al. Differences between medication-related osteonecrosis of the jaw caused by bisphosphonates and denosumab: Histological, molecular biological, and clinical studies. Cureus 16, e62855. https:\/\/doi.org\/10.7759\/cureus.62855 (2024).","DOI":"10.7759\/cureus.62855"},{"key":"20840_CR2","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1016\/j.ajpath.2014.07.010","volume":"184","author":"DW Williams","year":"2014","unstructured":"Williams, D. W. et al. Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti-receptor activator of NF-kappaB ligand antibody in mice. Am. J. Pathol. 184, 3084\u20133093. https:\/\/doi.org\/10.1016\/j.ajpath.2014.07.010 (2014).","journal-title":"Am. J. Pathol."},{"key":"20840_CR3","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2353\/ajpath.2010.090592","volume":"177","author":"Y Bi","year":"2010","unstructured":"Bi, Y. et al. Bisphosphonates cause osteonecrosis of the jaw-like disease in mice. Am. J. Pathol. 177, 280\u2013290. https:\/\/doi.org\/10.2353\/ajpath.2010.090592 (2010).","journal-title":"Am. J. Pathol."},{"key":"20840_CR4","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","volume":"80","author":"SL Ruggiero","year":"2022","unstructured":"Ruggiero, S. L. et al. American association of oral and maxillofacial surgeons\u2019 position paper on medication-related osteonecrosis of the Jaws-2022 update. J. Oral Maxillofac. Surg. 80, 920\u2013943. https:\/\/doi.org\/10.1016\/j.joms.2022.02.008 (2022).","journal-title":"J. Oral Maxillofac. Surg."},{"key":"20840_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jds.2023.04.026","volume":"19","author":"M Otsuru","year":"2024","unstructured":"Otsuru, M. et al. Risk factors for dental findings of the development of medication-related osteonecrosis of the jaw: Investigation of 3734 teeth in cancer patients receiving high dose antiresorptive agents. J. Dent. Sci. 19, 203\u2013210. https:\/\/doi.org\/10.1016\/j.jds.2023.04.026 (2024).","journal-title":"J. Dent. Sci."},{"key":"20840_CR6","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.bone.2016.06.011","volume":"90","author":"A Soundia","year":"2016","unstructured":"Soundia, A. et al. Osteonecrosis of the jaws (ONJ) in mice after extraction of teeth with periradicular disease. Bone 90, 133\u2013141. https:\/\/doi.org\/10.1016\/j.bone.2016.06.011 (2016).","journal-title":"Bone"},{"key":"20840_CR7","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1002\/jbmr.1894","volume":"28","author":"B Kang","year":"2013","unstructured":"Kang, B. et al. Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice. J. Bone Min. Res. 28, 1631\u20131640. https:\/\/doi.org\/10.1002\/jbmr.1894 (2013).","journal-title":"J. Bone Min. Res."},{"key":"20840_CR8","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1002\/jbmr.379","volume":"26","author":"TL Aghaloo","year":"2011","unstructured":"Aghaloo, T. L. et al. Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. J. Bone Min. Res. 26, 1871\u20131882. https:\/\/doi.org\/10.1002\/jbmr.379 (2011).","journal-title":"J. Bone Min. Res."},{"key":"20840_CR9","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1016\/j.ajpath.2018.06.019","volume":"188","author":"T Kim","year":"2018","unstructured":"Kim, T. et al. Removal of pre-existing periodontal inflammatory condition before tooth extraction ameliorates medication-related osteonecrosis of the Jaw-Like lesion in mice. Am. J. Pathol. 188, 2318\u20132327. https:\/\/doi.org\/10.1016\/j.ajpath.2018.06.019 (2018).","journal-title":"Am. J. Pathol."},{"key":"20840_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4614","author":"DW Williams","year":"2022","unstructured":"Williams, D. W. et al. Long-Term Ligature-Induced periodontitis exacerbates development of bisphosphonate-related osteonecrosis of the jaw in mice. J. Bone Min. Res. https:\/\/doi.org\/10.1002\/jbmr.4614 (2022).","journal-title":"J. Bone Min. Res."},{"key":"20840_CR11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00774-017-0872-1","volume":"36","author":"Y Akita","year":"2018","unstructured":"Akita, Y. et al. Effect of anti-angiogenesis induced by chemotherapeutic monotherapy, chemotherapeutic\/bisphosphonate combination therapy and anti-VEGFA mAb therapy on tooth extraction socket healing in mice. J. Bone Min. Metab. 36, 547\u2013559. https:\/\/doi.org\/10.1007\/s00774-017-0872-1 (2018).","journal-title":"J. Bone Min. Metab."},{"key":"20840_CR12","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.2174\/0929867324666170511113811","volume":"24","author":"L Antonuzzo","year":"2017","unstructured":"Antonuzzo, L. et al. Osteonecrosis of the jaw and angiogenesis inhibitors: A revival of a rare but serous side effect. Curr. Med. Chem. 24, 3068\u20133076. https:\/\/doi.org\/10.2174\/0929867324666170511113811 (2017).","journal-title":"Curr. Med. Chem."},{"key":"20840_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.bbcan.2014.05.002","volume":"1846","author":"RN Gacche","year":"2014","unstructured":"Gacche, R. N. & Meshram, R. J. Angiogenic factors as potential drug target: Efficacy and limitations of anti-angiogenic therapy. Biochim. Biophys. Acta 1846, 161\u2013179. https:\/\/doi.org\/10.1016\/j.bbcan.2014.05.002 (2014).","journal-title":"Biochim. Biophys. Acta"},{"key":"20840_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40729-019-0188-0","volume":"5","author":"G Maluf","year":"2019","unstructured":"Maluf, G., Caldas, R. J., Fregnani, E. R. & da Silva Santos, P. S. A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants. Int. J. Implant Dent. 5, 34. https:\/\/doi.org\/10.1186\/s40729-019-0188-0 (2019).","journal-title":"Int. J. Implant Dent."},{"key":"20840_CR15","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335\u20132342. https:\/\/doi.org\/10.1056\/NEJMoa032691 (2004).","journal-title":"N Engl. J. Med."},{"key":"20840_CR16","doi-asserted-by":"publisher","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia, J. et al. Bevacizumab (Avastin(R)) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat. Rev. 86, 102017. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102017 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"20840_CR17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","volume":"3","author":"N Ferrara","year":"2004","unstructured":"Ferrara, N., Hillan, K. J., Gerber, H. P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391\u2013400. https:\/\/doi.org\/10.1038\/nrd1381 (2004).","journal-title":"Nat. Rev. Drug Discov"},{"key":"20840_CR18","doi-asserted-by":"publisher","first-page":"115141","DOI":"10.1016\/j.bone.2019.115141","volume":"130","author":"JG Messer","year":"2020","unstructured":"Messer, J. G. et al. Anti-vascular endothelial growth factor antibody monotherapy causes destructive advanced periodontitis in rice rats (Oryzomys palustris). Bone 130, 115141. https:\/\/doi.org\/10.1016\/j.bone.2019.115141 (2020).","journal-title":"Bone"},{"key":"20840_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.bone.2016.02.020","volume":"86","author":"F Loi","year":"2016","unstructured":"Loi, F. et al. Inflammation, fracture and bone repair. Bone 86, 119\u2013130. https:\/\/doi.org\/10.1016\/j.bone.2016.02.020 (2016).","journal-title":"Bone"},{"key":"20840_CR20","doi-asserted-by":"publisher","first-page":"e0328459","DOI":"10.1371\/journal.pone.0328459","volume":"20","author":"S Kim","year":"2025","unstructured":"Kim, S. et al. Early cellular events of osteomucosal healing in the tooth extraction socket. PLoS One. 20, e0328459. https:\/\/doi.org\/10.1371\/journal.pone.0328459 (2025).","journal-title":"PLoS One"},{"key":"20840_CR21","doi-asserted-by":"publisher","first-page":"283","DOI":"10.5603\/EP.a2018.0031","volume":"69","author":"D Zou","year":"2018","unstructured":"Zou, D. et al. Th17 and IL-17 exhibit higher levels in osteonecrosis of the femoral head and have a positive correlation with severity of pain. Endokrynol. Pol. 69, 283\u2013290. https:\/\/doi.org\/10.5603\/EP.a2018.0031 (2018).","journal-title":"Endokrynol Pol."},{"key":"20840_CR22","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-13-0042","volume":"19","author":"Q Zhang","year":"2013","unstructured":"Zhang, Q. et al. IL-17-mediated M1\/M2 macrophage alteration contributes to pathogenesis of bisphosphonate-related osteonecrosis of the jaws. Clin. Cancer Res. 19, 3176\u20133188. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0042 (2013).","journal-title":"Clin. Cancer Res."},{"key":"20840_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.yexcr.2016.03.007","volume":"342","author":"FS Lakschevitz","year":"2016","unstructured":"Lakschevitz, F. S. et al. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp. Cell. Res. 342, 200\u2013209. https:\/\/doi.org\/10.1016\/j.yexcr.2016.03.007 (2016).","journal-title":"Exp. Cell. Res."},{"key":"20840_CR24","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/iwj.13139","volume":"16","author":"JW Ahn","year":"2019","unstructured":"Ahn, J. W. et al. Impaired wound healing secondary to bevacizumab. Int. Wound J. 16, 1009\u20131012. https:\/\/doi.org\/10.1111\/iwj.13139 (2019).","journal-title":"Int. Wound J."},{"key":"20840_CR25","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1007\/s10517-016-3206-8","volume":"160","author":"NA Bondarenko","year":"2016","unstructured":"Bondarenko, N. A. et al. Effect of vascular endothelial growth factor and erythropoietin on functional activity of fibroblasts and multipotent mesenchymal stromal cells. Bull. Exp. Biol. Med. 160, 498\u2013501. https:\/\/doi.org\/10.1007\/s10517-016-3206-8 (2016).","journal-title":"Bull. Exp. Biol. Med."},{"key":"20840_CR26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41374-019-0341-7","volume":"100","author":"CC Chung","year":"2020","unstructured":"Chung, C. C. et al. Vascular endothelial growth factor enhances profibrotic activities through modulation of calcium homeostasis in human atrial fibroblasts. Lab. Invest. 100, 285\u2013296. https:\/\/doi.org\/10.1038\/s41374-019-0341-7 (2020).","journal-title":"Lab. Invest."},{"key":"20840_CR27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3181\/00379727-161-40548","volume":"161","author":"JN Clore","year":"1979","unstructured":"Clore, J. N., Cohen, I. K. & Diegelmann, R. F. Quantitation of collagen types I and III during wound healing in rat skin. Proc. Soc. Exp. Biol. Med. 161, 337\u2013340. https:\/\/doi.org\/10.3181\/00379727-161-40548 (1979).","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"20840_CR28","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.2741\/543","volume":"4","author":"A Del Fattore","year":"2012","unstructured":"Del Fattore, A., Teti, A. & Rucci, N. Bone cells and the mechanisms of bone remodelling. Front. Biosci. Elite 4, 2302\u20132321. https:\/\/doi.org\/10.2741\/543 (2012).","journal-title":"Front. Bioscience-Elite"},{"key":"20840_CR29","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1084\/jem.190.2.293","volume":"190","author":"S Niida","year":"1999","unstructured":"Niida, S. et al. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J. Exp. Med. 190, 293\u2013298. https:\/\/doi.org\/10.1084\/jem.190.2.293 (1999).","journal-title":"J. Exp. Med."},{"key":"20840_CR30","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.matbio.2008.06.005","volume":"27","author":"Q Yang","year":"2008","unstructured":"Yang, Q. et al. VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and beta3-integrin. Matrix Biol. 27, 589\u2013599. https:\/\/doi.org\/10.1016\/j.matbio.2008.06.005 (2008).","journal-title":"Matrix Biol."},{"key":"20840_CR31","doi-asserted-by":"publisher","first-page":"14016","DOI":"10.1073\/pnas.0503544102","volume":"102","author":"S Niida","year":"2005","unstructured":"Niida, S. et al. VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 102, 14016\u201314021. https:\/\/doi.org\/10.1073\/pnas.0503544102 (2005).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"20840_CR32","doi-asserted-by":"publisher","first-page":"17349","DOI":"10.1074\/jbc.M115.652305","volume":"290","author":"S Park","year":"2015","unstructured":"Park, S. et al. Osteonecrosis of the jaw developed in mice: Disease variants regulated by \u03b3\u03b4 T cells in oral mucosal barrier immunity. J. Biol. Chem. 290, 17349\u201317366. https:\/\/doi.org\/10.1074\/jbc.M115.652305 (2015).","journal-title":"J. Biol. Chem."},{"key":"20840_CR33","doi-asserted-by":"publisher","first-page":"116168","DOI":"10.1016\/j.bone.2021.116168","volume":"153","author":"J Aguirre","year":"2021","unstructured":"Aguirre, J., Castillo, E. & Kimmel, D. Biologic and pathologic aspects of osteocytes in the setting of medication-related osteonecrosis of the jaw (MRONJ). Bone 153, 116168. https:\/\/doi.org\/10.1016\/j.bone.2021.116168 (2021).","journal-title":"Bone"},{"key":"20840_CR34","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1200\/JCO.23.02750","volume":"42","author":"DE Peterson","year":"2024","unstructured":"Peterson, D. E. et al. Prevention and management of osteoradionecrosis in patients with head and neck cancer treated with radiation therapy: ISOO-MASCC-ASCO guideline. J. Clin. Oncol. 42, 1975\u20131996. https:\/\/doi.org\/10.1200\/JCO.23.02750 (2024).","journal-title":"J. Clin. Oncol."},{"key":"20840_CR35","doi-asserted-by":"publisher","first-page":"e264","DOI":"10.1016\/j.prro.2024.02.008","volume":"14","author":"F Yang","year":"2024","unstructured":"Yang, F. et al. Osteoradionecrosis rates after head and neck radiation therapy: Beyond the numbers. Pract. Radiat. Oncol. 14, e264\u2013e275. https:\/\/doi.org\/10.1016\/j.prro.2024.02.008 (2024).","journal-title":"Pract. Radiat. Oncol."},{"key":"20840_CR36","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s00432-015-1974-6","volume":"141","author":"JM Straub","year":"2015","unstructured":"Straub, J. M. et al. Radiation-induced fibrosis: Mechanisms and implications for therapy. J. Cancer Res. Clin. Oncol. 141, 1985\u20131994. https:\/\/doi.org\/10.1007\/s00432-015-1974-6 (2015).","journal-title":"J. Cancer Res. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20840-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20840-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20840-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T09:55:16Z","timestamp":1761126916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-20840-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["20840"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-20840-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36903"}}